Latest Share Chat

REMOVE ADS

Astrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

13,858.00 304.00 (2.24%)

Bid:

13,842.00

Ask:

13,846.00

Spread: 4.00 (0.029%)

Market Cap: £214.92b

Last checked at -

Intraday Astrazeneca Share Chart

REMOVE ADS

EMTN Programme Routine Technical Update

11 Jun 2020 07:00

RNS Number : 6000P

AstraZeneca PLC

11 June 2020

11 June 2020 07:00 BST

EMTN Programme Routine Technical Update: Publication of Prospectus

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

The last drawdown under the EMTN programme was in 2016.

To view the full document, please paste the following URL into the address bar of your browser.

http://www.rns-pdf.londonstockexchange.com/rns/6000P_1-2020-6-10.pdf

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

http://www.morningstar.co.uk/uk/NSM

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PDIFLFFARAIILII

Date		Source	Headline
4th Jun 2021	7:05 am	RNS	Lynparza reduced recurrence risk in breast cancer
4th Jun 2021	7:00 am	RNS	AstraZeneca appoints new Chief Financial Officer
2nd Jun 2021	7:00 am	RNS	Publication of Final Terms
1st Jun 2021	3:01 pm	RNS	Block listing Interim Review
1st Jun 2021	3:00 pm	RNS	Total Voting Rights
28th May 2021	7:00 am	RNS	Tagrisso approved in EU in early lung cancer
27th May 2021	4:41 pm	RNS	Second Price Monitoring Extn
27th May 2021	4:36 pm	RNS	Price Monitoring Extension
27th May 2021	7:00 am	RNS	AstraZeneca prices a EUR800m bond offering
26th May 2021	9:24 am	RNS	Stabilisation Notice
26th May 2021	7:00 am	RNS	AstraZeneca prices a $7bn bond offering
25th May 2021	7:00 am	RNS	EMTN programme update - publication of Prospectus
21st May 2021	7:00 am	RNS	Vaxzevria COVID-19 vaccine approved in Japan
18th May 2021	3:30 pm	RNS	Director/PDMR Shareholding
11th May 2021	2:00 pm	RNS	Result of AGM
11th May 2021	1:55 pm	RNS	Shareholders vote in favour of Alexion acquisition
7th May 2021	7:00 am	RNS	Imfinzi + tremelimumab showed survival in POSEIDON
5th May 2021	6:30 pm	RNS	Holding(s) in Company
4th May 2021	3:00 pm	RNS	Total Voting Rights
4th May 2021	7:00 am	RNS	Farxiga approved in the US for CKD
30th Apr 2021	7:00 am	RNS	AZN: First quarter 2021 results
26th Apr 2021	7:10 am	RNS	Selumetinib recommended for EU approval in NF1
26th Apr 2021	7:05 am	RNS	Tagrisso adjuvant receives positive CHMP opinion
26th Apr 2021	7:00 am	RNS	Nirsevimab Phase III trial met primary endpoint
16th Apr 2021	12:00 pm	RNS	US clearance of proposed acquisition of Alexion
14th Apr 2021	7:00 am	RNS	Tagrisso approved in China in early lung cancer
12th Apr 2021	1:00 pm	RNS	Circular and notice of general meeting
12th Apr 2021	7:00 am	RNS	Update on Farxiga COVID-19 DARE-19 Phase III trial
1st Apr 2021	3:00 pm	RNS	Total Voting Rights
30th Mar 2021	12:15 pm	RNS	Notice of AGM
25th Mar 2021	3:00 pm	RNS	Director/PDMR Shareholding
25th Mar 2021	7:00 am	RNS	AZD1222 US Ph3 primary analysis confirms efficacy
22nd Mar 2021	7:00 am	RNS	AstraZeneca US vaccine trial met primary endpoint
16th Mar 2021	7:05 am	RNS	Divestment of Viela shareholding completed
16th Mar 2021	7:00 am	RNS	US supply agreement for additional AZD7442 doses
9th Mar 2021	3:00 pm	RNS	Director/PDMR Shareholding
4th Mar 2021	3:00 pm	RNS	Designation of EU home member state
3rd Mar 2021	7:00 am	RNS	US court decision favours Symbicort patents
2nd Mar 2021	7:00 am	RNS	Further update on roxadustat US regulatory review
1st Mar 2021	3:00 pm	RNS	Total Voting Rights
22nd Feb 2021	7:00 am	RNS	Voluntary withdrawal Imfinzi US bladder indication
17th Feb 2021	7:00 am	RNS	Lynparza: IDMC recommend early analysis of OlympiA
16th Feb 2021	11:15 am	RNS	Filing of Form 20-F with SEC
15th Feb 2021	3:00 pm	RNS	Director/PDMR Shareholding
15th Feb 2021	11:00 am	RNS	Annual Financial Report
11th Feb 2021	7:01 am	RNS	AstraZeneca Non-Executive Board changes
11th Feb 2021	7:00 am	RNS	AZN: full-year 2020 results
10th Feb 2021	7:00 am	RNS	Divestment of Crestor in Europe completed
5th Feb 2021	7:00 am	RNS	Update on KESTREL Phase III trial for Imfinzi
4th Feb 2021	7:00 am	RNS	Forxiga approved in China for heart failure

Latest Share Chat

Astrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Intraday Astrazeneca Share Chart

EMTN Programme Routine Technical Update

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending